WO2004091612A1 - A synergistic pharmaceutical combination comprising cicletanine for the prevention or treatment of diabetes - Google Patents

A synergistic pharmaceutical combination comprising cicletanine for the prevention or treatment of diabetes Download PDF

Info

Publication number
WO2004091612A1
WO2004091612A1 PCT/HU2004/000037 HU2004000037W WO2004091612A1 WO 2004091612 A1 WO2004091612 A1 WO 2004091612A1 HU 2004000037 W HU2004000037 W HU 2004000037W WO 2004091612 A1 WO2004091612 A1 WO 2004091612A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutically suitable
acid addition
cicletanine
addition salt
suitable acid
Prior art date
Application number
PCT/HU2004/000037
Other languages
French (fr)
Inventor
János EGRI
Original Assignee
SynoSens Kutató és Fejlesztő Kft.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SynoSens Kutató és Fejlesztő Kft. filed Critical SynoSens Kutató és Fejlesztő Kft.
Priority to YUP-2005/0776A priority Critical patent/RS20050776A/en
Priority to JP2006506248A priority patent/JP2006523668A/en
Priority to CA002522126A priority patent/CA2522126A1/en
Priority to EP04727331A priority patent/EP1648453A1/en
Publication of WO2004091612A1 publication Critical patent/WO2004091612A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide

Definitions

  • the invention refers to a synergistic pharmaceutical , combination suitable for the prevention or treatment of a prediabetic state, metabolic X-syndrome or diabetes mellitus as well as disorders which are associated with the states listed
  • NIDDM non-insulin-dependent diabetes mellitus
  • the aim of the invention is to provide a pharmaceutical combination which is suitable for the prevention of the development of diabetes or at least the complications that accompany diabetes, or, if such prevention is not possible anymore, for the efficient treatment of said complications.
  • cicletanine [chemical name ( ⁇ )-3-(4- chlorophenyl)-1 ,3-dihydro-6-methylfuro-[3,4-c]pyridin-7-ol], a known active agent having blood pressure lowering activity [US Patent No. 4,383,998 ], exerts an insulin sensitizing effect.
  • this available amount becomes sufficient to bring about the required physiological effect in the presence of cicletanine.
  • the administration of cycletanine enhances the sensitivity of insulin. Consequently, a lower dosage of insulin or an antidiabetic or anti-hyperlipidemic active agent administered to the patient is sufficient to produce the therapeutical effect.
  • a first object of the invention is to provide a synergistic pharmaceutical combination suitable for the prevention or treatment of a prediabetic state, metabolic X- syndrome or diabetes mellitus as well as disorders which are associated with the states listed above, namely endogenic metabolic disorders, insulin resistance, dislipidemia, alopecia, diffuse effluvium, polycystic ovary syndrome and/or other diabetic complications.
  • a second object of the invention is to provide the use of cicletanine for the preparation of a pharmaceutical composition having insulin sensitizing effect.
  • a third object of the invention is to provide a method for treating a patient suffering from or threatened by a prediabetic state, metabolic X-syndrome or diabetes mellitus as well as disorders which are associated with the states listed above, namely endogenic metabolic disorders, insulin resistance, dislipidemia, alopecia, diffuse effluvium, polycystic ovary syndrome and/or other diabetic complications with cicletanine.
  • the synergistic pharmaceutical combination of the invention comprises
  • a second pharmaceutical composition containing an antidiabetic or anti-hyperlipidemic active agent or, if desired and chemically possible, a pharmaceutically suitable acid addition salt or a salt formed with a pharmaceutically suitable base thereof and one or more conventional carrier(s).
  • a pharmaceutical combination is an association of two pharmaceutically active agents in which - either each of the active agents has been converted, one by one, to separate pharmaceutical compositions using one or more conventional carrier(s) and any of the usual processes of drug manufacture, and in this case the two sorts of pharmaceutical composition obtained are administered to the patient simultaneously or one after the other following an interval; or
  • the two active agents have been converted to one single pharmaceutical composition that can be administered to the patient being in need thereof.
  • the pharmaceutical composition may contain a mixture of the two active agents, or each of the active agents may be present at a different site in the pharmaceutical composition, e.g. one of them in the tablet core and the other in a coating of the tablet core.
  • one or more conventional carrier(s) and any of the usual processes of drug manufacture are used to prepare this single pharmaceutical composition.
  • any of the pharmacologically active agents conventionally used in the therapy for the treatment of diabetes is meant. These are mainly the following:
  • insulin in the first place, human insulin prepared by recombinant technology is employed, which is administered, in general, parenterally.
  • the insulin sensitizing active agents enhance the effect of insulin.
  • the most important sorts of them are the PPAR (peroxisome proliferator-activated receptor) ⁇ -agonists, for example the thiazolidinedione derivatives such as pioglitazone [( ⁇ )-5-[[4-[2-(5-ethyl-2-pyridinyI)ethoxy]phenyl]methyl]-2,4- thiazolidinedione], troglitazone [( ⁇ )-5-[[4-[(3,4-dihydro-6- hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]- phenyl]methyl]-2,4-thiazolidinedione], ciglitazone [5-[[4-[(1- methylcyclohexyl)methoxy]phenyl]methyl]-2,4-thiazolidine- dione, rosiglitazone [(+)-5-
  • the active agents that enhance the production of insulin are, for example, as follows: mitiglinide [( ⁇ S,3aR,7aS)- octahydro- ⁇ -oxo- ⁇ -(phenylmethyl)-2H-isoindole-2-butanoic acid], repaglinide [(S)-2-ethoxy-4-[2 ⁇ [[3-methyl-1-[2-(1- piperidinyl)phenyl]butyl]amino]-2-oxoethyI]benzoic acid], senaglinide (i.e. nateglinide) [N-[[(trans-4-(1-methylethyl)- cyclohexyl]carbonyl]-D-phenylalanine] or pharmaceutically suitable acid addition salts or pharmaceutically suitable salts thereof.
  • mitiglinide [( ⁇ S,3aR,7aS)- octahydro- ⁇ -oxo- ⁇ -(phenylmethyl)-2H
  • sulfonylurea derivatives e.g. tolbutamide [N-f(butylamino)- carbonyl]-4-methylbenzenesulfonamide], chlorpropamide [4- chloro-N-[(propylamino)carbonyl]benzenesulfonamide], tolazamide [N-[[(hexahydro-1 H-azepin-1-yl)amino]carbonyl]-4- methylbenzenesulfonamide], acetohexamide [4-acetyl-N- [(cyclohexylamino)carbonyl]benzenesulfonamide] etc.
  • tolbutamide N-f(butylamino)- carbonyl]-4-methylbenzenesulfonamide
  • chlorpropamide 4- chloro-N-[(propylamino)carbonyl]benzenesulfonamide]
  • tolazamide N-[[(hexahydro-1 H-a
  • glibenclamide [5-chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]- amino]sulfonyl]phenyl]ethyl]-2-methoxybenzamide]
  • glipizide [N-[2-[4-[[[(cyclohexyl-amino)carbonyl]amino]su!fonyl]phenyl]- ethyl]-5-methylpyrazine-carboxamide]
  • gliclazide [N-[[(hexa- hydrocyclopenta[c]pyrrol-2(1 H)-yl)amino]carbonyl]-4-methyl- benzenesulfonamide]
  • glimepiride [trans-3-ethyl-2,5-dihydro-4- methyl-N-[2-[4-[[[[[[(4-methylcyclohexylamino)carbonyl]- amino]sul
  • the most important biguanidine derivatives can be characterized by the formula R 1 R 3 ⁇ / N -C - NH - - C - N
  • R 1 , R 2 , R 3 and R 4 represent, independently, a hydrogen atom, a C- ⁇ - 1 0 alkyl group, a naphthyl group, a phenyl group or a phehyl(C ⁇ - alkyl) group, wherein in both former cases the phenyl group is optionally substituted by 1-3 substituents which can be, independently, a halo atom, a C ⁇ - 4 alkyl group . or a C ⁇ - 4 alkoxy group, with the proviso that one of R 1 , R 2 , R 3 and R 4 is other than a hydrogen atom, or
  • R 1 and R 2 together with the adjacent nitrogen atom and/or R 3 and R 4 together with the adjacent nitrogen atom form a 5- or 6-membered, saturated, unsaturated or aromatic ring that can be fused with a further 5- or 6-membered saturated, unsaturated or aromatic ring optionally containing also a nitrogen atom, and pharmaceutically suitable acid addition salts thereof.
  • Especially preferred biguanidine derivatives are metformin [N.N-dimethylimidocarbonimidic diamide], buformin [N- butylimidodicarbonimidic diamide] and phenformin [N-(2- phenylethyl)imidodicarbonimidic diamide].
  • the ⁇ -glucosidase inhibitors inhibit the enzyme ⁇ - glucosidase.
  • Important representants thereof are, for example, miglitol [1 ,5-dideoxy-1 ,5-[(2-hydroxyethyl)imino]-D-glucitol], acarbose [0-4,6-dideoxy-4-[[[1 S-(1 ⁇ ,4 ⁇ ,5 ⁇ ,6 ⁇ )]-4,5,6- trihydroxy-(3-hydroxymethyl)-2-cyclohexen-1 -yI]amino]- ⁇ -D- glucopyranosyl-(1 - 4)-0- ⁇ -D-glucopyranosyl-(1 -»4)-D- glucose], voglibose [3,4-dideoxy-4-[[2-hydroxy-1- (hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)-D-epiinositol] etc.
  • any of the pharmacologically active agents conventionally used in the therapy for the treatment of high blood-lipid level is meant. These are compounds that can be classified mainly as follows: aryloxyalkanoic acid derivatives, HMG coenzyme reductase inhibitors, nicotinic acid derivatives, antacids for bile acids. Out of the aryloxyalkanoic acid derivatives, preferred active agents are e.g.
  • lovastatin [[1S- [1 ⁇ (R * ),3 ⁇ ,7 ⁇ ,8 ⁇ (2S * ,4S * ),8 ⁇ ]]-2-methylbutanoic acid 1 ,2, 3,7,8, 8 ⁇ -hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4- hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester], fluvastatin [[R * ,S * -(E)]-(+)-7-[3-(4-fluorophenyl)-1 -(1 -methyl- ethyl)- 1 H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid], pravastatin [[1 S-[1 ⁇ ( ⁇ S * , ⁇ S*),2 ,6 ⁇ ,
  • nicotinic acid derivatives for example, the following ones are used: acipimox [5-methylpyrazinecarboxylic acid 4-oxide], niceritrol [3-pyridinecarboxylic acid 2,2-bis[[(3- pyridinylcarbonyl)oxy]methyl]-1 ,3-propanediyl ester], nicomol [3-pyridinecarboxylic acid (2-hydroxy-1 ,3-cyclohexane- diylidene)-tetrakis(methylene) ester], nicoclonate [3-pyridinecarboxylic acid 1-(4-chlorophenyl)-2-methylpropyl ester] etc.
  • colestipol a basic anion exchange resin: N- (2-aminoethyl)-N'-[2-[(2-aminoethyl)amino]-ethyl]-1 ,2-ethane- diamine polymer with (chloromethyl)oxirane]
  • cholestyramine a synthetic, strongly basic anion exchange resin containing quaternary ammonium functional groups which are attached to a styrene-divinylbenzene copolymer
  • polidexide an anion exchange resin containing quaternary ammonium groups which bind the bile acids in the intestine] etc.
  • the antidiabetic and anti-hyperlipidemic active agents are known from the literature. If desired and chemically possible, these active agents can be used in the form of the pharmaceutically suitable acid addition salts thereof or in the form of the salts formed with pharmaceutically suitable bases. Under a pharmaceutically suitable acid addition salt, an acid addition salt formed with a pharmaceutically suitable inorganic acid such as hydrogen chloride or sulfuric acid and the like, or with a pharmaceutically suitable organic acid such as acetic acid, fumaric acid, lactic acid and the like is meant.
  • a pharmaceutically suitable inorganic acid such as hydrogen chloride or sulfuric acid and the like
  • a pharmaceutically suitable organic acid such as acetic acid, fumaric acid, lactic acid and the like
  • the antidiabetic or anti-hyperlipidemic active agent has a chemical structure that can form a salt with a base
  • the salt of the active agent formed with a pharmaceutically suitable inorganic or organic base can be used.
  • said active agent can form an acid addition salt with an acid
  • a pharmaceutically suitable acid addition salt of the active agent can be employed, too.
  • the CM alkyl group can be a methyl, ethyl, n- propyl, isopropyl, n-butyl, sec,-butyl, tert.-butyl, or isobutyl group.
  • the C-MO alkyl group may be, in addition to the ones • listed above, for example, a pentyl, hexyl, heptyl, octyl, nonyl or decyl group, too.
  • a C ⁇ - alkoxy group can be, for example, a methoxy, ethoxy, n-propoxy or n-butoxy group.
  • a halo atom is, for example, a fluoro, chloro, bromo or iodo atom.
  • a 5- or 6- membered, saturated, unsaturated or aromatic ring containing a nitrogen atom is, for example, a pyrrole, isopyrrole, dihydro- pyrrole, pyrrolidine, pyridine, piperidine, dihydropyridine, tetra- hydropyridine ring or the like.
  • the mass (or weight) ratio of the cicletanine or a pharmaceutically suitable acid addition salt thereof and the antidiabetic or ahti-hyperlipidemic active agent or, if desired and chemically possible, a pharmaceutically suitable acid addition salt or a salt formed with a pharmaceutically suitable base thereof is, in general, (1 -100):(100-1 ).
  • the one or two pharmaceutical composition(s) of the pharmaceutical combination is/are suitable for peroral or parenteral administration and is/are solid or liquid composition(s).
  • the suitable dosage forms and manufacture thereof as well as the useful carriers are known from the literature e.g. Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, USA.
  • each active agent can be present in a separate pharmaceutical composition or both cicletanine and the antidiabetic or anti-hyperlipidemic active agent are present in a single common pharmaceutical composition.
  • the antidiabetic or anti-hyperlipidemic active agent can be, for example, one of the species listed above.
  • the preferred synergistic pharmaceutical combination of the invention may contain cicletanine or a pharmaceutically suitable acid addition salt thereof such as the hydrochloride as well as (b-i) an antidiabetic active agent e.g.
  • insulin or an insulin sensitizing active agent such as a thiazolidinedione derivative, for example, pioglitazone, troglitazone, ciglitazone, rosiglitazone, or an active agent that enhances the production of insulin such as mitiglinide, repaglinide, senaglinide, or a sulfonamide such as tolbutamide, chlorpropamide, tolazamide, acetohexamide, glyburide, glipizide, gliclazide, glimepiride, gliquidone, glibornuride, glisoxepid, glisentide, glisolamide, glybuzole, glyclopyramide, or a biguanidine derivative of the formula I, preferably metformin, buformin, phenformin, or an - glucosidase inhibitor such as miglitol, acarbose or voglibose, or (b 2 ) an anti
  • an aryloxyalkanoic acid derivative such as clofibrate, gemfibrozil, simfibrate, etofibrate, ciprofibrate, ronifibrate, or a HMG coenzyme reductase inhibitor such as lovastatin, fluvastatin, pravastatin, simvastatin, atorvastatin, or a nicotinic acid derivative such as acipimox, niceritrol, nicomol, nicoclonate, or an antacid for bile acids such as colestipol, cholestyramine, polidexide, or, if desired and chemically possible, a pharmaceutically suitable acid addition salt or a salt formed with a pharmaceutically suitable base of the species given under (b-i) and (b 2 ).
  • Human regular insulin was infused at a constant rate (13 mU/kg, NOVO Nordisk, Copenhagen) via one of the venous catheters over 120 min. This insulin infusion yielded plasma insulin immunoreactivity of 100+5 ⁇ U/ml in the steady state. This value corresponds to five times the value of the normal upper limit. Blood samples (0.3 ml) were taken from the arterial cannula for blood glucose concentration at 10 min intervals.
  • Blood glucose concentration was maintained constant (5.5+0.5 mmol/litre) by a variable rate of glucose infusion via the second venous cannula.
  • this condition we defined this condition as steady state.
  • additional blood samples 0.5 ml
  • the glucose infusion rate (mg/kg/min) during steady state was used to characterize insulin sensitivity [DeFronzo R.A. et al., Am. J. Of Physiol., 237, E214-223 (1979)].
  • test compound(s) was/were administered to healthy and hypercholesterolaemic animals, respectively, perorally, in a single dose, daily, for five days, and the glucose infusion rates determined on the 6 th day were averaged within each test group consisting of 6 animals.
  • One group of the healthy and one of the hypercholesterolaemic animals was used as the control. The results obtained are shown in Tables 1 , 2, and 3.
  • Insulin sensitivity as characterized by the glucose infusion rate in mg/kg/min during steady state
  • Insulin sensitivity as characterized by the glucose infusion rate in mg/kg/min during steady state
  • HC hypercholesterolaemic animals were used in the test.
  • Insulin sensitivity as characterized by the glucose infusion rate in mg/kg/min during steady state
  • HC hypercholesterolaemic animals were used in the test.
  • the amount of glucose infused to obtain constant blood glucose level has been measured in the above tests. It is favourable that a higher amount of glucose should be needed at the given constant blood glucose level which indicates the enhanced effect of insulin. Consequently, the higher glucose infusion rate is measured, the higher efficiency is obtained with the compound tested.
  • the especially preferred synergistic pharmaceutical combination of the invention contains (a) cicletanine or a pharmaceutically suitable acid addition salt thereof and (b) a biguanidine derivative of the formula I, suitably metformin, or a pharmaceutically suitable acid addition salt thereof, or a sulfonylurea, suitably glyburide, or a pharmaceutically suitable acid addition salt thereof, or a thiazolidinedione derivative, suitably troglitazone, or a pharmaceutically suitable acid addition salt thereof, wherein the active agents are present in separate pharmaceutical compositions or in a single pharmaceutical composition.
  • the invention includes also the use of cicletanine or a pharmaceutically suitable acid addition salt thereof for the preparation of a pharmaceutical composition having insulin sensitizing effect.
  • the pharmaceutical composition is a unit dosage form, in general, suitable for peroral or ' parenteral administration, and contains 30 to 100 mg of cicletanine or cicletanine hydrochloride.
  • the suitable dosage forms and manufacture thereof as well as the useful carriers are known from the literature e.g. Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, USA.
  • the insulin sensitizing effect of various doses of cicletanine was studied using similar tests employed in the study of glucose sensitivity of the synergistic pharmaceutical combination of the invention.
  • the animals were treated with 10 mg/kg, 30 mg/kg or 100 mg/kg of cicletanine, perorally, once daily, for 5 days.
  • the glucose infusion rate was determined on the 6 th day. The results obtained are shown in Table 4.
  • Insulin sensitivity as characterized by the glucose infusion rate in mg/kg/min during steady state
  • HC hypercholesterolaemic animals were used in the test.
  • the invention includes also a method for the treatment or the prevention of a prediabetic state, metabolic X-syndrome or diabetes mellitus as well as disorders which are associated with the states listed above, namely endogenic metabolic disorders, insulin resistance, dislipidemia, alopecia, diffuse effluvium, polycystic ovary syndrome and/or other diabetic complications, in which the patient suffering from or threatened by said states is treated with a therapeutically effective amount of cicletanine or a pharmaceutically suitable acid addition salt thereof.
  • the therapeutically effective amount of cicletanine is an amount that produces insulin sensitizing effect.
  • an antidiabetic or anti- hyperlipidaemic active agent can be administered to the patient suffering from or threatened by the states listed above.
  • the antidiabetic or anti-hyperlipidemic active agent and the cicletanine or a pharmaceutically suitable acid addition salt thereof can be administered simultaneously or one after the other following a shorter interval lasting for e.g. some seconds or minutes or a longer interval lasting for e.g. 10-30 minutes.
  • the daily dose of the antidiabetic or anti-hyperlipidemic agent is lower than the usual daily dose thereof employed in the conventional treatment when no cicletanine is administered.
  • the daily dose of cicletanine is, in general 30 to 100 mg, preferably about 50 mg for an adult person having a body weight of 70 kg.
  • - prediabetic state such as glucose intolerance or insulin resistance
  • IDDM IDDM
  • NIDDM NIDDM
  • a pharmaceutical composition containing cicletanine or a pharmaceutically suitable acid addition salt thereof can be administered to a patient that is treated or conventionally should be treated with an antidiabetic or anti-hyperlipidemic active agent in order to prevent or treat a prediabetic state, metabolic X-syndrome or diabetes mellitus as well as disorders which are associated with the states listed above, namely endogenic metabolic disorders, insulin resistance, dislipidemia, alopecia, diffuse effluvium, polycystic ovary syndrome and/or other diabetic complications.
  • the pharmaceutical composition containing cicletanine or a pharmaceutically suitable acid addition salt thereof As a result of the administration of the pharmaceutical composition containing cicletanine or a pharmaceutically suitable acid addition salt thereof, either no further treatment with an antidiabetic or anti-hyperlipidemic active agent is required, or a lower dosage of the antidiabetic or anti-hyperlipidemic active agent is sufficient.
  • a pharmaceutical composition containing cicletanine or a pharmaceutically suitable acid addition salt thereof as the active agent is administered to a patient suffering from diabetes and obtaining a regular insulin treatment, then the daily insulin dose can be reduced, thus, avoiding the development of insulin resistance.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention refers to a synergistic pharmaceutical combination which comprises (a) a first pharmaceutical composition containing cicletanine or a pharmaceutically suitable acid addition salt thereof and one or more conventional carrier(s), and (b) a second pharmaceutical composition containing an antidiabetic or anti-hyperlipidemic active agent or, if desired and chemically possible, a pharmaceutically suitable acid addition salt or a salt formed with a pharmaceutically suitable base thereof and one or more conventional carrier(s). The pharmaceutical combination is suitable for the prevention or treatment of, among others, diabetes mellitus.

Description

A SYNERGISTIC PHARMACEUTICAL COMBINATION COMPRISING CICLETANINE FOR THE PREVENTION OR TREATMENT OF DIABETES
The invention refers to a synergistic pharmaceutical , combination suitable for the prevention or treatment of a prediabetic state, metabolic X-syndrome or diabetes mellitus as well as disorders which are associated with the states listed
10 above, namely endogenic metabolic disorders, insulin resistance, dislipidemia, alopecia, diffuse effluvium, polycystic ovary syndrome and/or other diabetic complications.
In the industrially developed countries more and more human being suffers from diabetes. The frequency of the
15 disease is growing especially rapidly in the population above 50 of age. For example, the development of type 2 diabetes (i.e. non-insulin-dependent diabetes mellitus, NIDDM) is promoted by the defects in both the production and use of insulin. Genetic and environmental factors equally contribute to
20 the formation of this wide-spread serious disease accompanied by significant mortality. The patient treated with insulin or another antidiabetic or anti-hyperlipidemic agent obtains, as a matter of fact, only a palliative treatment that improves the life quality, however, the complications which accompany the
25 diabetes appear unavoidably. A significant part of the antidiabetic agents only enhances the production of insulin in the organism. The aim of the invention is to provide a pharmaceutical combination which is suitable for the prevention of the development of diabetes or at least the complications that accompany diabetes, or, if such prevention is not possible anymore, for the efficient treatment of said complications.
It has been found that cicletanine [chemical name (±)-3-(4- chlorophenyl)-1 ,3-dihydro-6-methylfuro-[3,4-c]pyridin-7-ol], a known active agent having blood pressure lowering activity [US Patent No. 4,383,998 ], exerts an insulin sensitizing effect. For example, in cases when insulin is produced by the organism in a decreased amount, this available amount becomes sufficient to bring about the required physiological effect in the presence of cicletanine. Also in patients suffering from insulin resistance, the administration of cycletanine enhances the sensitivity of insulin. Consequently, a lower dosage of insulin or an antidiabetic or anti-hyperlipidemic active agent administered to the patient is sufficient to produce the therapeutical effect.
Thus, a first object of the invention is to provide a synergistic pharmaceutical combination suitable for the prevention or treatment of a prediabetic state, metabolic X- syndrome or diabetes mellitus as well as disorders which are associated with the states listed above, namely endogenic metabolic disorders, insulin resistance, dislipidemia, alopecia, diffuse effluvium, polycystic ovary syndrome and/or other diabetic complications.
A second object of the invention is to provide the use of cicletanine for the preparation of a pharmaceutical composition having insulin sensitizing effect.
A third object of the invention is to provide a method for treating a patient suffering from or threatened by a prediabetic state, metabolic X-syndrome or diabetes mellitus as well as disorders which are associated with the states listed above, namely endogenic metabolic disorders, insulin resistance, dislipidemia, alopecia, diffuse effluvium, polycystic ovary syndrome and/or other diabetic complications with cicletanine. The synergistic pharmaceutical combination of the invention comprises
(a) a first pharmaceutical composition containing cicletanine or a pharmaceutically suitable acid addition salt thereof and one or more conventional carrier(s), and
(b) a second pharmaceutical composition containing an antidiabetic or anti-hyperlipidemic active agent or, if desired and chemically possible, a pharmaceutically suitable acid addition salt or a salt formed with a pharmaceutically suitable base thereof and one or more conventional carrier(s).
Definition of expressions used in the description and claims
A pharmaceutical combination is an association of two pharmaceutically active agents in which - either each of the active agents has been converted, one by one, to separate pharmaceutical compositions using one or more conventional carrier(s) and any of the usual processes of drug manufacture, and in this case the two sorts of pharmaceutical composition obtained are administered to the patient simultaneously or one after the other following an interval; or
- the two active agents have been converted to one single pharmaceutical composition that can be administered to the patient being in need thereof. In the latter case, the pharmaceutical composition may contain a mixture of the two active agents, or each of the active agents may be present at a different site in the pharmaceutical composition, e.g. one of them in the tablet core and the other in a coating of the tablet core. Of course, one or more conventional carrier(s) and any of the usual processes of drug manufacture are used to prepare this single pharmaceutical composition.
Under an antidiabetic active agent (bi) any of the pharmacologically active agents conventionally used in the therapy for the treatment of diabetes is meant. These are mainly the following:
- insulin,
- insulin sensitizing active agents, - active agents that enhance the production of insulin,
- sulfonamides,
- biguanidine derivatives and
- α-glucosidase inhibitors.
. As insulin, in the first place, human insulin prepared by recombinant technology is employed, which is administered, in general, parenterally.
The insulin sensitizing active agents enhance the effect of insulin. The most important sorts of them are the PPAR (peroxisome proliferator-activated receptor) γ-agonists, for example the thiazolidinedione derivatives such as pioglitazone [(±)-5-[[4-[2-(5-ethyl-2-pyridinyI)ethoxy]phenyl]methyl]-2,4- thiazolidinedione], troglitazone [(±)-5-[[4-[(3,4-dihydro-6- hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]- phenyl]methyl]-2,4-thiazolidinedione], ciglitazone [5-[[4-[(1- methylcyclohexyl)methoxy]phenyl]methyl]-2,4-thiazolidine- dione, rosiglitazone [(+)-5-[4-[2-[N-methyl-N-(2-pyridyl)amino]- ethόxy]benzyl]-2,4-thiazolidinedione] and other 2,4- thiazolidinedione derivatives as well as pharmaceutically suitable acid addition salts thereof.
The active agents that enhance the production of insulin are, for example, as follows: mitiglinide [(αS,3aR,7aS)- octahydro-γ-oxo-α-(phenylmethyl)-2H-isoindole-2-butanoic acid], repaglinide [(S)-2-ethoxy-4-[2~[[3-methyl-1-[2-(1- piperidinyl)phenyl]butyl]amino]-2-oxoethyI]benzoic acid], senaglinide (i.e. nateglinide) [N-[[(trans-4-(1-methylethyl)- cyclohexyl]carbonyl]-D-phenylalanine] or pharmaceutically suitable acid addition salts or pharmaceutically suitable salts thereof.
Out of the sulfonamides, the most important ones are the sulfonylurea derivatives e.g. tolbutamide [N-f(butylamino)- carbonyl]-4-methylbenzenesulfonamide], chlorpropamide [4- chloro-N-[(propylamino)carbonyl]benzenesulfonamide], tolazamide [N-[[(hexahydro-1 H-azepin-1-yl)amino]carbonyl]-4- methylbenzenesulfonamide], acetohexamide [4-acetyl-N- [(cyclohexylamino)carbonyl]benzenesulfonamide] etc. as first generation sulfonylureas or, for example, glyburide (glibenclamide) [5-chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]- amino]sulfonyl]phenyl]ethyl]-2-methoxybenzamide], glipizide [N-[2-[4-[[[(cyclohexyl-amino)carbonyl]amino]su!fonyl]phenyl]- ethyl]-5-methylpyrazine-carboxamide], gliclazide [N-[[(hexa- hydrocyclopenta[c]pyrrol-2(1 H)-yl)amino]carbonyl]-4-methyl- benzenesulfonamide], glimepiride [trans-3-ethyl-2,5-dihydro-4- methyl-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]- sulfonyl]phenyl]ethyl]-2-oxo-1 H-pyrrole-1-carboxamide], gliquidone [N-[(cyclohexyl-amino)carbonyl]-4-[2-(3,4-dihydro-7- methoxy-4,4-dimethyl-1 ,3-dioxo-2(1 H)-isoquinolinyl)ethyl]- benzenesulfonamide], glibomuride [N-[[(3-hydroxy-4,7,7- trimethylbicyclo[2.2.1]hept-2-yl)amino]carbonyl]-4-methyl- benzenesulfonamide], glisoxepid [N-[2-[4-[[[[(hexahydro-1 H- azepin-1 -yl)amino]carbonyl]amino]-sulfonyl]phenyl]ethyl]-5- methyl-3-isoxazolecarboxamide], glisentide [N-[2-[4-[[[(cyclo- pentylamino)-carbonyl]amino]sulfonyl]phenyl]-ethyl]-2- methoxybenzamide], glisolamide [N-[2-[4[[[(cyclohexyl- amino)carbonyl]amino]-sulfonyl]phenyl]ethyl]-5-methyl-3- isoxazolecarboxamide], glybuzole [N-[5-(1 ,1-dimethylethyl)- 1 ,3,4-thiadiazol-2-yl]benzenesulfonamide], glyclopyramide [4- chloro-N-[(1-pyrroiidinylamino)carbonyl]benzenesulfonamide] etc. as second generation sulfonylureas and pharmaceutically suitable acid addition salts thereof.
The most important biguanidine derivatives can be characterized by the formula R1 R3 \ / N -C - NH - - C - N
II ^
R2 NH NH R4
wherein
R1, R2, R3 and R4 represent, independently, a hydrogen atom, a C-ι-10 alkyl group, a naphthyl group, a phenyl group or a phehyl(Cι- alkyl) group, wherein in both former cases the phenyl group is optionally substituted by 1-3 substituents which can be, independently, a halo atom, a Cι-4 alkyl group . or a Cι-4 alkoxy group, with the proviso that one of R1, R2, R3 and R4 is other than a hydrogen atom, or
R1 and R2 together with the adjacent nitrogen atom and/or R3 and R4 together with the adjacent nitrogen atom form a 5- or 6-membered, saturated, unsaturated or aromatic ring that can be fused with a further 5- or 6-membered saturated, unsaturated or aromatic ring optionally containing also a nitrogen atom, and pharmaceutically suitable acid addition salts thereof. Especially preferred biguanidine derivatives are metformin [N.N-dimethylimidocarbonimidic diamide], buformin [N- butylimidodicarbonimidic diamide] and phenformin [N-(2- phenylethyl)imidodicarbonimidic diamide]. The α-glucosidase inhibitors inhibit the enzyme α- glucosidase. Important representants thereof are, for example, miglitol [1 ,5-dideoxy-1 ,5-[(2-hydroxyethyl)imino]-D-glucitol], acarbose [0-4,6-dideoxy-4-[[[1 S-(1 α,4α,5β,6α)]-4,5,6- trihydroxy-(3-hydroxymethyl)-2-cyclohexen-1 -yI]amino]-α-D- glucopyranosyl-(1 - 4)-0-α-D-glucopyranosyl-(1 -»4)-D- glucose], voglibose [3,4-dideoxy-4-[[2-hydroxy-1- (hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)-D-epiinositol] etc. Under an anti-hyperlipidemic active agent (b2) any of the pharmacologically active agents conventionally used in the therapy for the treatment of high blood-lipid level is meant. These are compounds that can be classified mainly as follows: aryloxyalkanoic acid derivatives, HMG coenzyme reductase inhibitors, nicotinic acid derivatives, antacids for bile acids. Out of the aryloxyalkanoic acid derivatives, preferred active agents are e.g. clofibrate [2-(4-chlorophenoxy)-2-methyl- propanoic acid ethyl ester], gemfibrozil [5-(2,5-dimethyI- phenoxy)-2,2-dimethylpentanoic acid], simfibrate [2-(4-chloro- phenoxy)-2-methylpropanoic acid 1 ,3-propanediyl ester], etofibrate [3-pyridinecarboxylic acid 2-[2-(4-chlorophenoxy)-2- methyl-1 -oxopropoxy]ethyl ester], ciprofibrate [2-[4-(2,2- dichIorocyclopropyI)phenoxy]-2-methylpropanoic acid], ronifibrate [3-pyridinecarboxylic acid 3-[2-(4-chIorophenoxy)-2- methyl-1-oxopropoxy]propyl ester] etc. Out of the HMG coenzyme reductase inhibitors, the most important active agents are the following: lovastatin [[1S- [1 α(R*),3α,7β,8β(2S*,4S*),8αβ]]-2-methylbutanoic acid 1 ,2, 3,7,8, 8α-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4- hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester], fluvastatin [[R*,S*-(E)]-(+)-7-[3-(4-fluorophenyl)-1 -(1 -methyl- ethyl)- 1 H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid], pravastatin [[1 S-[1 α(βS*,δS*),2 ,6α,8β(R*),8a ]]-1 ,2,6,7,8,8a- hexahydro-β,δ,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)- 1-naphthaleneheptanoic acid monosodium salt], simvastatin [[1 S-[1 α,3 ,7β,8β(2S*,4S*),8αβ]]-2,2-dimethyIbutanoic acid 1 ,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4- hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1 -naphthalenyl ester], atorvastatin [[R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1- methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1 H-pyrrole-1- heptanόic acid] etc.
Out of the nicotinic acid derivatives, for example, the following ones are used: acipimox [5-methylpyrazinecarboxylic acid 4-oxide], niceritrol [3-pyridinecarboxylic acid 2,2-bis[[(3- pyridinylcarbonyl)oxy]methyl]-1 ,3-propanediyl ester], nicomol [3-pyridinecarboxylic acid (2-hydroxy-1 ,3-cyclohexane- diylidene)-tetrakis(methylene) ester], nicoclonate [3-pyridinecarboxylic acid 1-(4-chlorophenyl)-2-methylpropyl ester] etc. Out of the antacids that bind the bile acids, important ones are the following: colestipol [a basic anion exchange resin: N- (2-aminoethyl)-N'-[2-[(2-aminoethyl)amino]-ethyl]-1 ,2-ethane- diamine polymer with (chloromethyl)oxirane], cholestyramine [a synthetic, strongly basic anion exchange resin containing quaternary ammonium functional groups which are attached to a styrene-divinylbenzene copolymer], polidexide [an anion exchange resin containing quaternary ammonium groups which bind the bile acids in the intestine] etc.
The antidiabetic and anti-hyperlipidemic active agents are known from the literature. If desired and chemically possible, these active agents can be used in the form of the pharmaceutically suitable acid addition salts thereof or in the form of the salts formed with pharmaceutically suitable bases. Under a pharmaceutically suitable acid addition salt, an acid addition salt formed with a pharmaceutically suitable inorganic acid such as hydrogen chloride or sulfuric acid and the like, or with a pharmaceutically suitable organic acid such as acetic acid, fumaric acid, lactic acid and the like is meant.
When the antidiabetic or anti-hyperlipidemic active agent has a chemical structure that can form a salt with a base, also the salt of the active agent formed with a pharmaceutically suitable inorganic or organic base can be used. When said active agent can form an acid addition salt with an acid, a pharmaceutically suitable acid addition salt of the active agent can be employed, too.
In formula I, the CM alkyl group can be a methyl, ethyl, n- propyl, isopropyl, n-butyl, sec,-butyl, tert.-butyl, or isobutyl group. The C-MO alkyl group may be, in addition to the ones • listed above, for example, a pentyl, hexyl, heptyl, octyl, nonyl or decyl group, too. A Cι- alkoxy group can be, for example, a methoxy, ethoxy, n-propoxy or n-butoxy group. A halo atom is, for example, a fluoro, chloro, bromo or iodo atom. A 5- or 6- membered, saturated, unsaturated or aromatic ring containing a nitrogen atom is, for example, a pyrrole, isopyrrole, dihydro- pyrrole, pyrrolidine, pyridine, piperidine, dihydropyridine, tetra- hydropyridine ring or the like.
In the synergistic pharmaceutical combination of the invention, the mass (or weight) ratio of the cicletanine or a pharmaceutically suitable acid addition salt thereof and the antidiabetic or ahti-hyperlipidemic active agent or, if desired and chemically possible, a pharmaceutically suitable acid addition salt or a salt formed with a pharmaceutically suitable base thereof is, in general, (1 -100):(100-1 ). In general, the one or two pharmaceutical composition(s) of the pharmaceutical combination is/are suitable for peroral or parenteral administration and is/are solid or liquid composition(s). The suitable dosage forms and manufacture thereof as well as the useful carriers are known from the literature e.g. Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, USA. In the synergistic pharmaceutical combination of the invention, each active agent can be present in a separate pharmaceutical composition or both cicletanine and the antidiabetic or anti-hyperlipidemic active agent are present in a single common pharmaceutical composition. The antidiabetic or anti-hyperlipidemic active agent can be, for example, one of the species listed above. Thus, the preferred synergistic pharmaceutical combination of the invention may contain cicletanine or a pharmaceutically suitable acid addition salt thereof such as the hydrochloride as well as (b-i) an antidiabetic active agent e.g. insulin, or an insulin sensitizing active agent such as a thiazolidinedione derivative, for example, pioglitazone, troglitazone, ciglitazone, rosiglitazone, or an active agent that enhances the production of insulin such as mitiglinide, repaglinide, senaglinide, or a sulfonamide such as tolbutamide, chlorpropamide, tolazamide, acetohexamide, glyburide, glipizide, gliclazide, glimepiride, gliquidone, glibornuride, glisoxepid, glisentide, glisolamide, glybuzole, glyclopyramide, or a biguanidine derivative of the formula I, preferably metformin, buformin, phenformin, or an - glucosidase inhibitor such as miglitol, acarbose or voglibose, or (b2) an anti-hyperlipidemic active agent e.g. an aryloxyalkanoic acid derivative such as clofibrate, gemfibrozil, simfibrate, etofibrate, ciprofibrate, ronifibrate, or a HMG coenzyme reductase inhibitor such as lovastatin, fluvastatin, pravastatin, simvastatin, atorvastatin, or a nicotinic acid derivative such as acipimox, niceritrol, nicomol, nicoclonate, or an antacid for bile acids such as colestipol, cholestyramine, polidexide, or, if desired and chemically possible, a pharmaceutically suitable acid addition salt or a salt formed with a pharmaceutically suitable base of the species given under (b-i) and (b2). The influence of the combination of the invention on the glucose sensitivity was studied using the following tests. All experiments performed conform to the European Community guiding principles for the care and use of experimental animals.
Adult male New Zealand white rabbits weighing 3-3.2 kg, housed in an animal room (12-hour light/dark periods a day, temperature of 22-25 °C, relative humidity of 50-70 %) with one animal per pen, fed commercial laboratory chow and tap water ad libitum, were used throughout. The animals underwent surgery after a two-week adaptation period [Szilvassy Z. et al., Br. J. Pharmacol., 112, 999-1001 (1994)].
Surgery was performed under aseptic conditions. The rabbits were anaesthetized with an intravenous bolus of 10 mg/kg diazepam (Sigma, St. Louis, MO, USA) and 5 mg/kg ketamine (EGIS Pharmaceuticals Ltd., Budapest, Hungary). Lidocaine (EGIS Pharmaceuticals Ltd., Budapest, Hungary) was administered subcutaneously for local pain relief. Poly- ethylene catheters were inserted into two major branches of the jugular vein and the left carotid artery. The catheters were exteriorised through the back of the neck. These lines were kept patent by filling with sodium heparin solution (100 lU/ml). Human regular insulin was infused at a constant rate (13 mU/kg, NOVO Nordisk, Copenhagen) via one of the venous catheters over 120 min. This insulin infusion yielded plasma insulin immunoreactivity of 100+5 μU/ml in the steady state. This value corresponds to five times the value of the normal upper limit. Blood samples (0.3 ml) were taken from the arterial cannula for blood glucose concentration at 10 min intervals.
Blood glucose concentration was maintained constant (5.5+0.5 mmol/litre) by a variable rate of glucose infusion via the second venous cannula. When blood glucose had stabilized for at least 30 min, we defined this condition as steady state. In the steady state, additional blood samples (0.5 ml) were taken for plasma insulin determination at 10-min intervals. The glucose infusion rate (mg/kg/min) during steady state was used to characterize insulin sensitivity [DeFronzo R.A. et al., Am. J. Of Physiol., 237, E214-223 (1979)]. The test compound(s) was/were administered to healthy and hypercholesterolaemic animals, respectively, perorally, in a single dose, daily, for five days, and the glucose infusion rates determined on the 6th day were averaged within each test group consisting of 6 animals. One group of the healthy and one of the hypercholesterolaemic animals was used as the control. The results obtained are shown in Tables 1 , 2, and 3.
Table 1
Insulin sensitivity as characterized by the glucose infusion rate in mg/kg/min during steady state
Group Control Cicletanine Metformin Cicletanine of (30 mg/kg) (100 (30 mg/kg) animals p.o. mg/kg) + p.o. metformin
(100 mg/kg) p.o. normal 13,8+1 ,11 16,2±1 ,35 14,4±1 ,03 19,4+1 ,32
HC 7,9±1 ,3 14,2+1 ,31 10,7±1 ,01 15,6+1 ,12 normal = healthy animals were used in the test; HC = hypercholesterolaemic animals were used in the test.
Table 2
Insulin sensitivity as characterized by the glucose infusion rate in mg/kg/min during steady state
Group Control Cicletanine Troglitazone Cicletanine of (30 mg/kg) (75 mg/kg) (30 mg/kg) animals p.o. p.o. + troglitazone
-
(75 mg/kg) p.o. normal 13,2±0,98 16,9±1 ,13 14,3+0,08 19,8+2,00
HC 8,2+0,76 13,5+1 ,41 13,2+1 ,06 15,7+0,99
normal = healthy animals were used in the test; HC = hypercholesterolaemic animals were used in the test.
Table 3
Insulin sensitivity as characterized by the glucose infusion rate in mg/kg/min during steady state
Group Control Cicletanine Glyburide Cicletanine of (30 mg/kg) (1 mg/kg) (30 mg/kg) animals p.o. p.o. + glyburϊde
(1 mg/kg) p.o. normal 13,44+0,86 15,9+0,89 11 ,8+1 ,38 16,4+2,22
HC 8,4+1 ,09 12,9+1 ,06 7,0+1 ,00 14,91+0,78
normal = healthy animals were used in the test;
HC = hypercholesterolaemic animals were used in the test.
As a matter of fact, the amount of glucose infused to obtain constant blood glucose level has been measured in the above tests. It is favourable that a higher amount of glucose should be needed at the given constant blood glucose level which indicates the enhanced effect of insulin. Consequently, the higher glucose infusion rate is measured, the higher efficiency is obtained with the compound tested.
As seen in Table 1 , in healthy animals, of course, higher values are obtained than in hypercholesterolaemic ones. In the control groups, lower glucose infusion rates are experienced than in the groups treated with either cicletanine or metformin. Anyway, in both healthy and cholesterolaemic animals, the glucose infusion rates are significantly higher when the animals has been treated with both cicletanine and metformin than in the case when only one of the test compounds has been administered. Thus, synergism is observed between cicletanine and metformin.
The situation is the same with cicletanine and troglitazone as well as cicletanine and glyburide as shown by Table 2 and Table 3, respectively.
Thus, the especially preferred synergistic pharmaceutical combination of the invention contains (a) cicletanine or a pharmaceutically suitable acid addition salt thereof and (b) a biguanidine derivative of the formula I, suitably metformin, or a pharmaceutically suitable acid addition salt thereof, or a sulfonylurea, suitably glyburide, or a pharmaceutically suitable acid addition salt thereof, or a thiazolidinedione derivative, suitably troglitazone, or a pharmaceutically suitable acid addition salt thereof, wherein the active agents are present in separate pharmaceutical compositions or in a single pharmaceutical composition.
The invention includes also the use of cicletanine or a pharmaceutically suitable acid addition salt thereof for the preparation of a pharmaceutical composition having insulin sensitizing effect. Preferably, the pharmaceutical composition is a unit dosage form, in general, suitable for peroral or ' parenteral administration, and contains 30 to 100 mg of cicletanine or cicletanine hydrochloride. The suitable dosage forms and manufacture thereof as well as the useful carriers are known from the literature e.g. Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, USA.
The insulin sensitizing effect of various doses of cicletanine was studied using similar tests employed in the study of glucose sensitivity of the synergistic pharmaceutical combination of the invention. The animals were treated with 10 mg/kg, 30 mg/kg or 100 mg/kg of cicletanine, perorally, once daily, for 5 days. The glucose infusion rate was determined on the 6th day. The results obtained are shown in Table 4.
Table 4
Insulin sensitivity as characterized by the glucose infusion rate in mg/kg/min during steady state
Group Control Cicletanine Cicletanine Cicletanine of (10 mg/kg) (30 mg/kg) (100 mg/kg) animals p.o. p.o. p.o. normal 13,44+0,86 14,9+1 ,11 16,8+1 ,52 15,9+0,83
HC 8,4±1 ,09 11 ,2+1 ,21 13,5+1 ,41 14,26+1 ,16
normal = healthy animals were used in the test;
HC = hypercholesterolaemic animals were used in the test.
As a matter of fact, in the latter test the influence of various doses of cicletanine on the utilization of insulin produced by the pancreas was studied. From tha data of Table 4 it can be seen that, relative to the control group, even a peroral dosage of as low as 10 mg/kg of cicletanine enhances the utilization of insulin produced by the organism in both healthy and hypercholesterolaemic animals. (The control data indicate the amount of glucose to be administered by infusion which amount is required to produce an euglycaemic state in hyper- insuiinaemic animals.) Of course, the higher doses of cicletanine produced still favourable utilizations of insulin. The invention includes also a method for the treatment or the prevention of a prediabetic state, metabolic X-syndrome or diabetes mellitus as well as disorders which are associated with the states listed above, namely endogenic metabolic disorders, insulin resistance, dislipidemia, alopecia, diffuse effluvium, polycystic ovary syndrome and/or other diabetic complications, in which the patient suffering from or threatened by said states is treated with a therapeutically effective amount of cicletanine or a pharmaceutically suitable acid addition salt thereof. The therapeutically effective amount of cicletanine is an amount that produces insulin sensitizing effect.
In addition to cicletanine or a pharmaceutically suitable acid addition salt thereof, if desired, also an antidiabetic or anti- hyperlipidaemic active agent can be administered to the patient suffering from or threatened by the states listed above. In this case the antidiabetic or anti-hyperlipidemic active agent and the cicletanine or a pharmaceutically suitable acid addition salt thereof can be administered simultaneously or one after the other following a shorter interval lasting for e.g. some seconds or minutes or a longer interval lasting for e.g. 10-30 minutes. Since the cicletanine synergistically enhances the therapeutical effect of the antidiabetic or anti-hyperlipidemic active agent, the daily dose of the antidiabetic or anti- hyperlipidemic agent is lower than the usual daily dose thereof employed in the conventional treatment when no cicletanine is administered.
The daily dose of cicletanine is, in general 30 to 100 mg, preferably about 50 mg for an adult person having a body weight of 70 kg.
Using the process of the invention, the development of especially the following clinical patterns can be prevented, or, when once developed, they can be influenced advantageously: - prediabetic state such as glucose intolerance or insulin resistance,
- metabolic X-syndrome,
- both types of diabetes (IDDM and NIDDM),
- diabetic complications with special regards to retinopathy, neuropathy, nephropathy, polycystic ovary syndrome
(PCOS), alopecia, diffuse effluvium, gestation diabetes mellitus (GDM), arterial hypertonia, dislipidemia, arteriosclerosis, obesitas, cardial ischemia associated with diabetes etc. Thus, a pharmaceutical composition containing cicletanine or a pharmaceutically suitable acid addition salt thereof can be administered to a patient that is treated or conventionally should be treated with an antidiabetic or anti-hyperlipidemic active agent in order to prevent or treat a prediabetic state, metabolic X-syndrome or diabetes mellitus as well as disorders which are associated with the states listed above, namely endogenic metabolic disorders, insulin resistance, dislipidemia, alopecia, diffuse effluvium, polycystic ovary syndrome and/or other diabetic complications. As a result of the administration of the pharmaceutical composition containing cicletanine or a pharmaceutically suitable acid addition salt thereof, either no further treatment with an antidiabetic or anti-hyperlipidemic active agent is required, or a lower dosage of the antidiabetic or anti-hyperlipidemic active agent is sufficient. When a pharmaceutical composition containing cicletanine or a pharmaceutically suitable acid addition salt thereof as the active agent is administered to a patient suffering from diabetes and obtaining a regular insulin treatment, then the daily insulin dose can be reduced, thus, avoiding the development of insulin resistance.

Claims

Claims:
1. A synergistic pharmaceutical combination suitable for the prevention or treatment of a prediabetic state, metabolic X- syndrome or diabetes mellitus as well as disorders which are associated with the states listed above, namely endogenic metabolic disorders, insulin resistance, dislipidemia, alopecia, diffuse effluvium, polycystic ovary syndrome and/or other diabetic complications comprising
(a) a first pharmaceutical composition containing cicletanine or a pharmaceutically suitable acid addition salt thereof and one or more conventional carrier(s), and
(b) a second pharmaceutical composition containing an antidiabetic or anti-hyperlipidemic active agent or, if desired and chemically possible, a pharmaceutically suitable acid addition salt or a salt formed with a pharmaceutically suitable base thereof and one or more conventional carrier(s).
2. A pharmaceutical combination of Claim 1 in which a single pharmaceutical composition comprises both the cicletanine or a pharmaceutically suitable acid addition salt thereof and the antidiabetic or anti-hyperlipidemic active agent or, if desired and chemically possible, a pharmaceutically suitable acid addition salt or a salt formed with a pharmaceutically suitable base thereof.
3. A pharmaceutical combination of Claim 1 or 2 comprising a thiazolidinedione derivative or a pharmaceutically suitable acid addition salt thereof as the antidiabetic active agent.
4. A pharmaceutical combination of Claim 1 or 2 comprising a sulfonylurea or a pharmaceutically suitable acid addition salt thereof as the antidiabetic active agent.
5. A pharmaceutical combination of Claim 1 or 2 comprising a biguanidine derivative of the formula I, wherein
R1 R3
\ /
N -C - NH - - C - N
/ II II \
R2 NH NH R4
wherein
R1, R2, R3 and R4 represent, independently, a hydrogen atom, a C-MO alkyl group, a naphthyl group, a phenyl group or a phenyl(Cι_4 alkyl) group, wherein in both former cases the phenyl group is optionally substituted by 1-3 substituents which can be, independently, a halo atom, a Cι- alkyl group or a C1-4 alkoxy group, with the proviso that one of R1, R2, R3 and R4 is other than a hydrogen atom, or
R1 and R2 together with the adjacent nitrogen atom and/or R3 and R4 together with the adjacent nitrogen atom form a 5- or 6-membered, saturated, unsaturated or aromatic ring that can be fused with a further 5- or 6-membered saturated, unsaturated or aromatic ring optionally containing also a 1 nitrogen atom, or a pharmaceutically suitable acid addition salt thereof as the antidiabetic active agent.
6. A pharmaceutical combitanion of Claim 5 comprising metformin or a pharmaceutically suitable acid addition salt thereof as the antidiabetic active agent.
7. A pharmaceutical combination of Claim 1 or 2 comprising insulin, pioglitazone, troglitazone, ciglitazone, rosiglitazone, mitiglinide, repaglinide, senaglinide, tolbutamide, chlorpropamide, tolazamide, acetohexamide, glyburide, glipizide, gliclazide, glimepiride, gliquidone, glibomuride, glisoxepid, glibenclamide, glisentide, glisolamide, glybuzole, glyclopyramide, metformin, buformin, phenformin, miglitol, acarbose or voglibose, clofibrate, gemfibrozil, simfibrate, etofibrate, ciprofibrate, ronifibrate, lovastatin, fluvastatin, pravastatin, simvastatin, atorvastatin, acipimox, niceritrol, nicomol, nicoclonate, colestipol, cholestyramine, polidexide or, if desired and chemically possible, a pharmaceutically suitable acid addition salt or a salt formed with a pharmaceutically suitable base thereof as the antidiabetic or anti-hyperlipidemic active agent.
8. Use of cicletanine or a pharmaceutically suitable acid addition salt thereof for the preparation of a pharmaceutical composition having insulin sensitizing effect.
9. The use of Claim 5 in which each pharmaceutical composition contains 30 to 100 mg of cicletanine or cicletanine hydrochloride.
10. A method for the treatment or the prevention of a prediabetic state, metabolic X-syndrome or diabetes mellitus as well as disorders which are associated with the states listed above, namely endogenic metabolic disorders, insulin resistance, dislipidemia, alopecia, diffuse effluvium, polycystic ovary syndrome and/or other diabetic complications, in which the patient suffering from or threatened by said states is treated with a therapeutically effective amount of cicletanine or a pharmaceutically suitable acid addition salt thereof.
PCT/HU2004/000037 2003-04-15 2004-04-14 A synergistic pharmaceutical combination comprising cicletanine for the prevention or treatment of diabetes WO2004091612A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
YUP-2005/0776A RS20050776A (en) 2003-04-15 2004-04-14 A synergistic pharmaceutical combination comprising cicletanine for the prevention or treatment diabetes
JP2006506248A JP2006523668A (en) 2003-04-15 2004-04-14 Synergistic pharmaceutical combination containing cicletanine for the prevention or treatment of diabetes
CA002522126A CA2522126A1 (en) 2003-04-15 2004-04-14 A synergistic pharmaceutical combination comprising cicletanine for the prevention or treatment of diabetes
EP04727331A EP1648453A1 (en) 2003-04-15 2004-04-14 A synergistic pharmaceutical combination comprising cicletanine for the prevention or treatment of diabetes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0300990A HUP0300990A2 (en) 2003-04-15 2003-04-15 Synergistic combination for the prophylaxis and treatment of diabetes
HUP0300990 2003-04-15

Publications (1)

Publication Number Publication Date
WO2004091612A1 true WO2004091612A1 (en) 2004-10-28

Family

ID=90001685

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HU2004/000037 WO2004091612A1 (en) 2003-04-15 2004-04-14 A synergistic pharmaceutical combination comprising cicletanine for the prevention or treatment of diabetes

Country Status (6)

Country Link
EP (1) EP1648453A1 (en)
JP (1) JP2006523668A (en)
CA (1) CA2522126A1 (en)
HU (1) HUP0300990A2 (en)
RS (1) RS20050776A (en)
WO (1) WO2004091612A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021039A1 (en) * 2003-08-29 2005-03-10 Cotherix, Inc. Combination of cicletanine and an oral antidiabetic and/or blood lipid-lowering agent for treating diabetes and metabolic syndrome
WO2005025673A1 (en) * 2003-09-08 2005-03-24 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent
EP1804795A2 (en) * 2004-09-22 2007-07-11 Cornett, Glen Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
WO2009012223A1 (en) * 2007-07-13 2009-01-22 Gilead Sciences, Inc. Compositions for the treatment of metabolic disorders

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070275996A1 (en) * 2003-12-16 2007-11-29 Michele Bortolini Use of Statins For The Treatment Of Metabolic Syndrome
US9492422B2 (en) 2009-11-13 2016-11-15 Toray Industries, Inc. Therapeutic or prophylactic agent for diabetes
ES2869423T3 (en) * 2011-08-08 2021-10-25 Immunomet Therapeutics Inc N1-cyclic amine-N5-substituted phenylbiguanide derivatives and pharmaceutical composition comprising the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383998A (en) * 1981-02-10 1983-05-17 Societe De Conseils De Recherches Et D'applications Scientifiques Furo-(3,4-c)-pyridine derivatives and their pharmaceutical use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4383998A (en) * 1981-02-10 1983-05-17 Societe De Conseils De Recherches Et D'applications Scientifiques Furo-(3,4-c)-pyridine derivatives and their pharmaceutical use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAYES M C ET AL: "A drug interaction study between cicletanine and tolbutamide in healthy volunteers", EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol. 50, no. 5, 1996, pages 381 - 384, XP002293344, ISSN: 0031-6970 *
BRINGER J ET AL: "The choice of antihypertensive drugs for diabetic patients", REVUE FRANCAISE D'ENDOCRINOLOGIE CLINIQUE - NUTRITION ET METABOLISME 1992 FRANCE, vol. 33, no. 4-5, 1992, pages 337 - 345, XP009035504, ISSN: 0048-8062 *
DURAN M J ET AL: "Protective effect of cicletanine on renal function in uninephrectomized diabetic spontaneously hypertensive rats", EUROPEAN HEART JOURNAL, vol. 20, no. ABSTR. SUPPL., August 1999 (1999-08-01), & XXIST CONGRESS OF THE EUROPEAN SOCIETY OF CARDIOLOGY; BARCELONA, SPAIN; AUGUST 28-SEPTEMBER 1, 1999, pages 422, XP009035503, ISSN: 0195-668X *
KOHZUKI MASAHIRO ET AL: "Renal-protective effect of nondepressor dose of cicletanine in diabetic rats with hypertension", AMERICAN JOURNAL OF HYPERTENSION, vol. 13, no. 3, March 2000 (2000-03-01), pages 298 - 306, XP002293342, ISSN: 0895-7061 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021039A1 (en) * 2003-08-29 2005-03-10 Cotherix, Inc. Combination of cicletanine and an oral antidiabetic and/or blood lipid-lowering agent for treating diabetes and metabolic syndrome
GB2423927A (en) * 2003-08-29 2006-09-13 Cotherix Inc Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome
WO2005025673A1 (en) * 2003-09-08 2005-03-24 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity comprising a hypoglycemic agent
EP1804795A2 (en) * 2004-09-22 2007-07-11 Cornett, Glen Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
EP1804795A4 (en) * 2004-09-22 2007-11-07 Cornett Glen Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease
WO2009012223A1 (en) * 2007-07-13 2009-01-22 Gilead Sciences, Inc. Compositions for the treatment of metabolic disorders

Also Published As

Publication number Publication date
EP1648453A1 (en) 2006-04-26
HUP0300990D0 (en) 2003-06-28
HUP0300990A2 (en) 2005-05-30
JP2006523668A (en) 2006-10-19
CA2522126A1 (en) 2004-10-28
RS20050776A (en) 2007-11-15

Similar Documents

Publication Publication Date Title
US8048873B2 (en) Synergistic pharmaceutical combination for the prevention or treatment of diabetes
RU2207850C2 (en) Pharmaceutical composition comprising metformin and fibrate in combination and its using in preparing medicinal agents designated for hyperglycemia reduction
US20060111428A1 (en) Combination of an dpp-iv inhibitor and a ppar-alpha compound
KR100566701B1 (en) Use of alpha-glucosidase inhibitors for treating high-risk impaired glucose tolerance
AU2002354884A1 (en) A synergistic pharmaceutical combination for the prevention or treatment of diabetes
KR20040075935A (en) Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
KR20010089635A (en) Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
JP2004537550A5 (en)
US4656177A (en) Analgesic and anti-inflammatory compositions comprising caffeine and methods of using same
US5849762A (en) Peripherally acting anti-pruritic opiates
EP1648453A1 (en) A synergistic pharmaceutical combination comprising cicletanine for the prevention or treatment of diabetes
JP2005515984A (en) Pharmaceutical composition having a combination of metformin and 4-oxobutanoic acid and its application in the treatment of diabetes
US20090197917A1 (en) Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes
AU2001282010A1 (en) Pharmaceutical composition comprising metformin and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative
JP2008530189A (en) Use of rimonabant to prepare a medicament that can be used in the prevention and treatment of type 2 diabetes
CN1840195A (en) A synergistic pharmaceutical combination for the prevention or treatment of diabetes

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-2005/0776

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2522126

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 171422

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006506248

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004727331

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004727331

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004727331

Country of ref document: EP